A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

NCT02625636 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: SAR438544
DRUG: placebo
DRUG: r-glucagon

Sponsor

Sanofi